| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10614638 | IVR | 1 mg/kg | 1 mg/kg | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 4 mg/kg | 4 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:11714251 | IVR | 100 mg/L | 100 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/L | 100 mg/L | Elevated biliary T4 excretion | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:15997204 | IVR | 10 mg/kg | 10 mg/kg | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:16759992 | IVR | 500 mg/kg/day | 500 mg/kg/day | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects Wnt signaling pathway | Developmental endocrine-mediated perturbations | |
| PMID:17889981 | IVR | 2 mg/kg | 2 mg/kg | Affects superoxide dismutase (SOD) levels | Hepatic endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Reduced femur weights | Developmental endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased Acid phosphatase (ACP) activity in the liver | Hepatic endocrine-mediated perturbations | |
| PMID:18602130 | IVR | 6 mg/kg/day | 6 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects calcium transport | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| PMID:19337518 | IVR | 1 mg/kg/day | - | No significant effects observed | - |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects spatial learning | Neurological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:21783486 | IVR | 262 mg/kg | 262 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 262 mg/kg | 262 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:24642964 | IVR | 6 mg/kg/day | 6 mg/kg/day | Affects catecholamine biosynthesis | Metabolic endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 6 mg/kg/day | 6 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:24711995 | IVR | 10 mg/L | 10 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| PMID:25572879 | IVR | 30 mg/kg/day | 30 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| PMID:26432769 | IVR | 10 mg/kg | 10 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| PMID:27614457 | IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects folliculogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:28739394 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Increased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Affects sertoli cells function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | 0.5 mg/kg/day | Increased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| PMID:29208485 | IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased weights of epididymis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased LH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects steroidogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | 2 mg/kg/day | Decreased estradiol levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased LH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased weights of epididymis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects anogenital distance in offspring | D | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects steroidogenesis in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased LH levels in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased weights of seminal vesicles in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects steroidogenesis in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects anogenital distance in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased weights of epididymis in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testis weights in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased estradiol levels in offspring | ||
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased testosterone levels in offspring | ||
| PMID:30917103 | IVR | 1 mg/kg | 1 mg/kg | Oxidative stress in nervous system in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Abnormal neuronal distribution in offspring | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| PMID:4213067 | IVR | 25 mg/kg | 25 mg/kg | Elevated biliary T4 excretion | Metabolic endocrine-mediated perturbations |
| IVR | 25 mg/kg | 25 mg/kg | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations | |
| PMID:8812251 | IVR | 1 mg/kg | 1 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 4 mg/kg | 4 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 8 mg/kg | 8 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.